Advertisement

Dermatomyositis

  • Jeffrey P. Callen

Abstract

Dermatomyositis (DM) is one of the idiopathic inflammatory myopathies (IIM) (Callen 2000; Plotz et al. 1995; Targoff 1991). In 1975, Bohan and Peter published a classical article that first suggested a set of criteria to aid in the diagnosis and classification of DM and polymyositis (PM). Four of the five criteria related to the muscle disease: 1) progressive proximal symmetrical weakness 2) elevated muscles enzymes, 3) an abnormal electromyogram and 4) an abnormal muscle biopsy, while the fifth was the presence of compatible cutaneous disease. It was felt that DM differed from PM only by the presence of cutaneous disease. Recent studies of the pathogenesis of the myopathy have been controversial, some suggesting that the myopathies in DM and PM are pathogenetically different with DM being due to a vascular inflammation (Kuru et al. 2000) while other studies of cytokines suggest that the processes are similar (Wanchu et al. 1999; Shimizu et al. 2000; Sugiura et al. 2000; Nyberg et al. 2000). There has been a renewed interest in the pathogenetic mechanisms involved in the myopathy with recent studies revealing abnormal levels of nitric oxide, elevation of circulating tumor necrosis factor receptors, elevated soluble CD40 expression, and increased expression of interleukin 1-alpha within the muscle. The pathogenesis of the cutaneous disease is poorly understood.

Keywords

Muscle Disease Inclusion Body Myositis Cutaneous Manifestation Idiopathic Inflammatory Myopathy Cutaneous Lupus Erythematosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abernethy ML, Arterberry JF, Callen JP (1996)Low-dose methotrexate as an adjunctive therapy with surgery for ectropion complicating dermatomyositis. Dermatology 192(2): 153–155PubMedCrossRefGoogle Scholar
  2. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM (2000a) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27: 2498–2503PubMedGoogle Scholar
  3. Al-Mayouf S, Al-Mazyed A, Bahabri S (2000b) Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 19: 138–141PubMedCrossRefGoogle Scholar
  4. Airio A, Pukkala E, Isomäki (1995) Elevated cancer incidence in patients with dermatomyositis: A population based study. J Rheumatol 22: 1300–1303Google Scholar
  5. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292: 344–347 and 403–407 (two part article)Google Scholar
  6. Bohan A, Peter JB, Bowman RL, Pearson CM (1977) A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56: 255–286PubMedCrossRefGoogle Scholar
  7. Callen JP (1982) The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol 6: 253–259PubMedCrossRefGoogle Scholar
  8. Callen JP (1993) Photodermatitis in a 6-year-old child. Arhthritis Rheum 36: 1483–1485CrossRefGoogle Scholar
  9. Callen AM, Pachman LM, Hayford J, Chung A, Ramsey-Goldman R (1994) Intermittent high dose intravenous methylprednisolone (IV pulse) prevents calcinosis and shortens disease course in juvenile dermatomyositis (JDMS). Arth Rheum 37: R10AGoogle Scholar
  10. Callen JP (1999) Photosensitivity in collagen vascular diseases. Semin Cutan Med Surg 18 (4): 293–296PubMedCrossRefGoogle Scholar
  11. Callen JP (2000) Dermatomyositis. Lancet 355: 53–57PubMedCrossRefGoogle Scholar
  12. Cheong W-K, Hughes GRV, Norris PG, Hawk JLM (1994) Cutaneous photosensitivity in dermatomyositis. Brit J Dermatol 131: 205–208CrossRefGoogle Scholar
  13. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: A nationwide cohort study in Denmark. Cancer Causes and Control 5: 9–13Google Scholar
  14. Cosnes A, Amaudric F, Gherardi R, Verroust J, Wechsler J, Revuz J, Roujeau JC (1995) Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 131: 1381–1385PubMedCrossRefGoogle Scholar
  15. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993–2000PubMedCrossRefGoogle Scholar
  16. Dalakas MC (1998) Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 54: 1509–1512CrossRefGoogle Scholar
  17. Daoud MS, Gibson LE, Pittelkow MR (1997) Hydroxyurea dermopathy. A unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 36: 178–182Google Scholar
  18. Dourmishev AL, Dourshimev LA (1999) Dermatomyositis and drugs. Adv Exp Med Biol 445: 187–191CrossRefGoogle Scholar
  19. Euwer RL, Sontheimer RD (1991) Amyopathic DM ( DM siné myositis ). J Am Acad Dermatol 24: 959–966Google Scholar
  20. Garcia J (2000) MRI in inflammatory myopathies. Skeletal Radiol 29: 425–438PubMedCrossRefGoogle Scholar
  21. Gelber AC, Nousari HC, Wigley FM (2000) Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 27: 1542–1545PubMedGoogle Scholar
  22. Ghali FE, Stein LD, Fine J-D, Burkes EJ, McCauliffe DP (1999) Gingival telangiectases. An underappreciated physical sign of juvenile dermatomyositis. Arch Dermatol 135: 1370–1374Google Scholar
  23. Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, Rosas E, Suarez-Almazor M, Cardona-Munoz C, Ramos-Remus C (1996) Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol 14: 373–379PubMedGoogle Scholar
  24. Hengstman G, van den Hoogen F, van Engelen B, Barrera P, Netea M, van den Putte L (2000) Anti-TNF-blockade with infliximab (remicade) in polymyositis and dermatomyositis. Arthritis Rheum 43: S193AGoogle Scholar
  25. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evan SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet 357: 96–100Google Scholar
  26. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P (2000) Medium-and long-tern functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43: 541–549PubMedCrossRefGoogle Scholar
  27. Kasteler JS, Callen JP (1994) Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed. JAMA 272: 1939–1941Google Scholar
  28. Kasteler JS, Callen JP (1997) Low-dose methotrexate administered weekly in an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 36: 67–71PubMedCrossRefGoogle Scholar
  29. Kaufmann R, Greiner D, Schmidt P, Wolter M (1998) Dermatomyositis presenting as plaque-like mucinosis. Brit J Dermatol 138: 889–892CrossRefGoogle Scholar
  30. Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-a expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99: 585–588PubMedCrossRefGoogle Scholar
  31. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70 (6): 360–374PubMedCrossRefGoogle Scholar
  32. Lundberg IE, Nyberg P (1998) New developments in the role of cytokines and chemokines in inflammatory myopathies.Curr Opinion in Rheumatol 10: 521–529CrossRefGoogle Scholar
  33. Marie I, Hatron P-Y, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B (1998) Pulmo- nary involvement in polymyositis and in dermatomyositis. J Rheumatol 25: 1336–1343PubMedGoogle Scholar
  34. Marie I, Hatron PY, Levesque H, Hachulla E, Hellot MF, Michon-Pasturel U, Courtois H, Devulder B (1999) Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine 78: 139–147PubMedCrossRefGoogle Scholar
  35. Marie I, Joly P, Levesque H, Heron F, Courville P, Cailleux N, Courtois H (2000) Pseudo-dermatomyositis as a complication of hydroxyurea therapy. Clin Exp Rheumatol 18: 536–537PubMedGoogle Scholar
  36. McCollough ML, Cockerell CJ (1998) Vesiculo-Bullous Dermatomyositis. Am J Dermatopathol 20: 170–174PubMedCrossRefGoogle Scholar
  37. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, Fraser DD, Dalakas M, Plotz PH (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326: 1380–1384PubMedCrossRefGoogle Scholar
  38. Nousari HC, Ha VT, Laman SD, Provost TT, Tausk FA (1999) ‘Centripetal Flagellate Erythema’: A Cutaneous Manifestation Associated with Dermatomyositis. J Rheumatol 26: 692–695Google Scholar
  39. Nyberg P, Wikman A-L, Nennesmo I, Lundberg I (2000) Increased expression of Interleukin la and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 27: 940–948PubMedGoogle Scholar
  40. Oliveri MB, Palermo R, Mautalen C, Hübscher O (1996) Regression of calcinosis during Diltiazem treatment of juvenile dermatomyositis. J Rheumatol 23: 2152–2155PubMedGoogle Scholar
  41. Pachman LM (1995) An update on juvenile dermatomyositis. Curr Opin Rheumatol 7: 437–441PubMedCrossRefGoogle Scholar
  42. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, Chen EH (2000) TNFa-308A allele in juvenile dermatomyositis. Arthritis Rheum 43: 2368–2377PubMedCrossRefGoogle Scholar
  43. Pautas E, Cherin P, Piette J-C, Pelletier S, Wechsler B, Cabane J, Herson S (2000) Features of polymyositis and dermatomyositis in the elderly: A case-control study. Clin Exp Rheumatol 18: 241–244Google Scholar
  44. Peng J-C, Sheem T-S, Hsu M-M (1995) Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases. Arch Otolaryngol Head Neck Surg 121: 1298–1301PubMedCrossRefGoogle Scholar
  45. Plotz PH, Rider LG, Targoff IN, Raben N, O’Hanlon TP, Miller FW (1995) Myositis Immunologic Contributions to Understanding Cause, Pathogenesis, and Therapy. Ann Intern Med 122: 715–724Google Scholar
  46. Requena L, Grilli R, Soriano L, Escalonilla P, Farina C, Martin L (1997) Dermatomyositis with a pityriasis rubra pilaris-like eruption: a little-known distinctive cutaneous manifestation of dermatomyositis. Brit J Dermatol 136: 768–771CrossRefGoogle Scholar
  47. Rockerbie NR, Woo TY, Callen JP, Giustina T (1989) Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol 20: 629–632PubMedCrossRefGoogle Scholar
  48. Saadeh CK (2000) Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents. Arhtritis Rheum 43: S193AGoogle Scholar
  49. Sawhney S, Sidoti G, Woo P, Murray KJ (2000) Clinical characteristics and outcome of idiopathic inflammatory myositis (IIM) in childhood: A 2 year follow up. Arthritis Rheum 43: 1CrossRefGoogle Scholar
  50. Sayers ME, Chou SM, Calabrese LH (1992) Inclusion body myositis: Analysis of 32 cases. J Rheumatol 19: 1385–1389PubMedGoogle Scholar
  51. Shannon PL, Ford MJ (1999) Angiokeratomas in juvenile dermatomyositis. Pediatr Dermatol 16: 448–451PubMedCrossRefGoogle Scholar
  52. Shimizu T, Tornita Y, Son K, Nishinarita S, Sawada S, Horie T (2000) Elevation of serum soluble tumor necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 19: 352–359PubMedCrossRefGoogle Scholar
  53. Spiera R, Kagen L (1998) Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opinion in Rheumatol 10: 556–561CrossRefGoogle Scholar
  54. Siguregeirsson B, Lindelöf B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 325: 363–367CrossRefGoogle Scholar
  55. Sinoway PA, Callen JP (1993) Chlorambucil: An Effective Corticosteroid-Sparing Agent for Patients with Recalcitrant Dermatomyositis. Arthritis Rheum 36: 319–324Google Scholar
  56. Sugugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, Hara M, Kamatani N (2000) Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: Role of CD40–CD40 ligand interaction in IL-6, IL-8, IL-5, and monocyte chemoattractant protein-1 production. J Immunol 164: 6593–6000Google Scholar
  57. Stonecipher MR, Jorizzo JL, White WL, Walker FO, Prichard E (1993) Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: DM siné myositis? J Am Acad Dermatol 28: 951–956PubMedCrossRefGoogle Scholar
  58. Targoff IN (1991) Dermatomyositis and polymyositis. Curr Prob Dermatol 3: 131–180CrossRefGoogle Scholar
  59. Targoff IN, Trieu EP, Sontheimer RD (2000) Autoantibodies to 155 kd and Se antigens in patients with clinically-amyopathic dermatomyositis. Arthritis Rheum 43: S194AGoogle Scholar
  60. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafvova J, Bartunkova J, Nemcova D, Charvat F (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29: 95–102PubMedCrossRefGoogle Scholar
  61. Villalba L, Adams EM (1996) Update on therapy for refractory dermatomyositis and polymyositis. Curr Opinion Rheumatol 8: 544–551CrossRefGoogle Scholar
  62. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, Miller FW (1998) Treatment of refractory myositis. A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41 (3): 392–399PubMedCrossRefGoogle Scholar
  63. Wanchu A, Khullar M, Sud A, Bambery P (1999) Nitric oxide production is increased in patient with inflammatory myositis. Nitric Oxide 3: 454–458PubMedCrossRefGoogle Scholar
  64. Whitmore SE, Rosenshein NB, Provost TT (1994) Ovarian cancer in patients with dermatomyositis. Medicine 73: 153–160PubMedCrossRefGoogle Scholar
  65. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C (1984) Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 10: 592–600PubMedCrossRefGoogle Scholar
  66. Woo TR, Rasmussen J, Callen JP (1985) Recurrent photosensitive dermatitis preceding juvenile dermatomyositis. Pediatr Dermatol 2: 207–212PubMedCrossRefGoogle Scholar
  67. Wortmann RL (2001) Idiopathic Inflammatory diseases of muscle. In Treatment of the Rheumatic Diseases. Weisman ML, Weinblatt ME, Louie JS (eds) W. B. Saunders Co. pp 390–402Google Scholar
  68. Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD (1995) Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 32: 754–757PubMedCrossRefGoogle Scholar
  69. Zuber M, John S, Pfreundschuh M, Gause A (1996) A young woman with a photosensitive pruritic rash on her face and upper trunk Arthritis Rheum 39: 1419–1422Google Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • Jeffrey P. Callen

There are no affiliations available

Personalised recommendations